AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 14521743
Drug: Mefloquine (750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mefloquine (750 mg single dosage)
Trial: 14521743
Drug: Artesunate (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artesunate (600 mg total dosage for five days, doubling dosage on the first day)
Trial: 6233176
Drug: Clomiphene citrate
RxNorm normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clomiphene citrate (CC) + Dexamethasone (DEX) 0.5 mg
Trial: 6233176
Drug: Clomiphene citrate
RxNorm normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clomiphene citrate (CC) 50 mg on days 5 to 9
Trial: 30808567
Drug: RV5 (pentavalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RV5 (pentavalent rotavirus vaccine)
Trial: 22798531
Drug: 15 mL
RxNorm normalized name: ethanol 0.15 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mL of mepivacaine 1.5% followed by 15 mL of bupivacaine 0.5% (group A)
Trial: 22798531
Drug: 15 mL
RxNorm normalized name: ethanol 0.15 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mL of bupivacaine 0.5% followed by 15 mL of mepivacaine 1.5% (group B)
Trial: 7608278
Drug: iv dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: iv dexamethasone (2.0‐16.0 mg/day)
Trial: 2222952
Drug: felodipine 10
RxNorm normalized name: felodipine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: felodipine 10 mg extended release once daily
Trial: 25690418
Drug: 30 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 g/day heat-stabilized rice bran (SRB) for 28 days
Trial: 21327796
Drug: Salbutamol 10
RxNorm normalized name: Salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Salbutamol 10 μg/min
Trial: 21327796
Drug: Salbutamol 20
RxNorm normalized name: Salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Salbutamol 20 μg/min
Trial: 25180798
Drug: Armodafinil 250
RxNorm normalized name: armodafinil 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Armodafinil 250 mg
Trial: 16684437
Drug: Armodafinil 150
RxNorm normalized name: armodafinil 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Armodafinil 150 mg and 250 mg
Trial: 15614594
Drug: Cognitive behavior
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavior therapy (N=65)
Trial: 3115786
Drug: DFMO (1.7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DFMO (1.7 g/m sq. t.i.d. added to conventional chemotherapy)
Trial: 3115786
Drug: Conventional chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional chemotherapy only (control group of 32 patients)
Trial: 29362444
Drug: Active minocycline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active minocycline (100 mg b.i.d.) + active aspirin (81 mg b.i.d.) (M + A)
Trial: 29362444
Drug: Active minocycline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active minocycline + placebo aspirin (M + P)
Trial: 29362444
Drug: Placebo-minocycline +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo-minocycline + active aspirin (A + P)
Trial: 29362444
Drug: Placebo-minocycline +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo-minocycline + placebo aspirin (P + P)
Trial: 24033822
Drug: 2% niacinamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% niacinamide + 2% tranexamic acid (TXA) cream (test formulation; n = 21)
Trial: 24033822
Drug: Vehicle control
RxNorm normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle control cream (n = 21)
Trial: 19026251
Drug: Triple-bead mixed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple-bead mixed amphetamine salts (MAS) (12.5 mg to 75 mg)
Trial: 12663706
Drug: No adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No adjuvant therapy or a single cycle of perioperative chemotherapy for node-negative disease (1,275 women)
Trial: 12663706
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy of at least 3 months' duration and/or tamoxifen for node-positive disease (4,077 women)
Trial: 10972581
Drug: Diet therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet therapy for 3 months
Trial: 9370178
Drug: Sequential therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential therapy with anti-thymocyte globulin (ATG) 20 mg/kg/d for 7 to 14 days
Trial: 9370178
Drug: CsA 8
RxNorm normalized name: CsA
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CsA 8 mg/kg/d started immediately before surgery with diltiazem 60 mg sustained release twice daily
Trial: 9370178
Drug: Sequential therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential therapy with anti-thymocyte globulin (ATG)
Trial: 1583321
Drug: Single 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single 5 x 10(8) cfu dose
Trial: 1583321
Drug: Single 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single 5 x 10(9) cfu dose
Trial: 1583321
Drug: Second 5
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Second 5 x 10(9) cfu dose one week later
Trial: 1583321
Drug: Increasing vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increasing vaccine dose to 5 x 10(9) cfu
Trial: 3896281
Drug: Nicardipine (average
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicardipine (average daily dose 84 mg, range 40-160 mg)
Trial: 22352509
Drug: Vocoders that
RxNorm normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vocoders that simulated aspects of cochlear implant processing
Trial: 15778880
Drug: Donepezil (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donepezil (up to 10 mg/day for 8 weeks)
Trial: 11836593
Drug: Intravesical instillation
RxNorm normalized name: ADSTILADRIN Suspension for Intravesical Instillation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravesical instillation of anticancer drug alone (method A)
Trial: 11836593
Drug: Intravesical instillation
RxNorm normalized name: ADSTILADRIN Suspension for Intravesical Instillation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravesical instillation plus oral chemotherapy (doxifluridine, 5'‐DFUR) (method B)
Trial: 8750168
Drug: Propranolol (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (160 mg/d for 1 week)
Trial: 8750168
Drug: Aspirin stimulation
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin stimulation test
Trial: 1897264
Drug: Western therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western therapy (dihydrochlorothiazide and atenolol)
Trial: 1897264
Drug: Chinese traditional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese traditional therapy (mixtures of nine herbs and other ingredients)
Trial: 31471753
Drug: Low-dose CT
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose CT angiography using ASiR-V
Trial: 28113240
Drug: Closed-loop insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Closed-loop insulin delivery over 12 weeks
Trial: 24982375
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg doxorubicin loaded Super Absorbent Polymer microspheres
Trial: 24982375
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg doxorubicin loaded Super Absorbent Polymer microspheres
Trial: 24982375
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg doxorubicin loaded Super Absorbent Polymer microspheres
Trial: 24982375
Drug: 0 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mg (bland embolic)
Trial: 24982375
Drug: Bland embolic
RxNorm normalized name: Io-Blend
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bland embolic vs drug-loaded groups
Trial: 3392652
Drug: Caffeine (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (600 mg)
Trial: 9219047
Drug: Dextroamphetamine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextroamphetamine (20 mg)
Trial: 17845167
Drug: 0.5% malathion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% malathion gel (30 minutes application)
Trial: 17845167
Drug: Ovide Lotion
RxNorm normalized name: malathion Topical Lotion [Ovide]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ovide Lotion (0.5% malathion)
Trial: 15447735
Drug: Itraconazole (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itraconazole (200 mg once a day for four days)
Trial: 11678783
Drug: Grapefruit juice
RxNorm normalized name: grapefruit juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grapefruit juice (200 ml, double strength, three times a day for 2 days)
Trial: 9834260
Drug: SR27417A (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SR27417A (10 mg/day)
Trial: 1103617
Drug: Buffered infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buffered infusion fluid or 24-hour change of administration set
Trial: 1103617
Drug: Antibiotic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic therapy with inline filters
Trial: 26203826
Drug: 120 mg
RxNorm normalized name: papain 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 mg tabalumab every 4 weeks (120/Q4W)
Trial: 26203826
Drug: 90 mg
RxNorm normalized name: papain 90 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90 mg tabalumab every 2 weeks (90/Q2W)
Trial: 16481387
Drug: Inhaled corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled corticosteroids (daily doses of </=500 microg)
Trial: 28796990
Drug: Granulocyte/monocyte apheresis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granulocyte/monocyte apheresis (GMA) with the Adacolumn as remission induction therapy
Trial: 25924545
Drug: Single Flap
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single Flap Approach (SFA) with rhPDGF‐BB (0.3 mg/ml) + β‐TCP
Trial: 25924545
Drug: Double Flap
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double Flap Approach (DFA) with rhPDGF‐BB (0.3 mg/ml) + β‐TCP
Trial: 23470303
Drug: α-lipoic acid
RxNorm normalized name: α-lipoic acid
DrugBank: Lipoic acid (DB00166)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: α-lipoic acid supplementation (1000 mg daily for 14 days)
Trial: 14622079
Drug: Problem-solving therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Problem-solving therapy (PST) with significant other
Trial: 10606851
Drug: Identical cream
RxNorm normalized name: MENTHOL 20 g in 100 mL TOPICAL EMULSION [DentiCalm]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Identical cream with 5% salicylic acid, omitting sodium nitrite
Trial: 2228838
Drug: Ceftriaxone 1
RxNorm normalized name: ceftriaxone 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone 1 g iv
Trial: 121165
Drug: Prophylactic granulocyte
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic granulocyte transfusions (daily at least 1.1010 granulocytes per square meter from the last day of treatment until the 12th day of aplasia)
Trial: 28234436
Drug: Immediate discontinuation
RxNorm normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate discontinuation of prior antipsychotics at baseline
Trial: 28234436
Drug: Gradual discontinuation
RxNorm normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gradual discontinuation of prior antipsychotics by reducing 25% each week
Trial: 15821379
Drug: Butorphanol 0.04
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Butorphanol 0.04 mg/kg
Trial: 9778225
Drug: Intravenous pulse
RxNorm normalized name: dulse extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous pulse administration of cyclophosphamide (0.75 gm/m2)
Trial: 9778225
Drug: Daily oral
RxNorm normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral cyclophosphamide treatment (2 mg/kg body weight)
Trial: 27484113
Drug: High intensity
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High intensity focused ultrasound (HIFU) treatment
Trial: 27484113
Drug: Whole lesion
RxNorm normalized name: scabies lesion lysate (human)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole lesion ablation (comparison for treatment time)
Trial: 20201089
Drug: Ferumoxytol (Feraheme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ferumoxytol (Feraheme injection) administered as two 510 mg IV injections, separated by 3-8 days
Trial: 20201089
Drug: Oral iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral iron (Ferro-Sequels) administered at a dose of 100 mg twice daily for 21 days
Trial: 11227291
Drug: Certoparin (18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Certoparin (18 mg)
Trial: 11227291
Drug: Dalteparin (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dalteparin (30 mg)
Trial: 11227291
Drug: Enoxaparin (24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin (24 mg)
Trial: 12796608
Drug: Tamoxifen 40
RxNorm normalized name: tamoxifen 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen 40 mg daily
Trial: 8390529
Drug: Enalapril pretreatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril pretreatment (5 mg/day for 5 days)
Trial: 8390529
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Enalapril and Noradrenaline
Trial: 2894971
Drug: Felodipine (initial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Felodipine (initial dose 2.5mg bid, titrated to 5, 10, 20mg bid)
Trial: 2894971
Drug: Prazosin (initial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prazosin (initial dose 0.5mg bid, titrated to 1, 2, 4mg bid)
Trial: 30352054
Drug: GSK3532795 (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK3532795 (60 mg, 120 mg, or 180 mg QD) + TDF/FTC (300/200 mg QD)
Trial: 30352054
Drug: Efavirenz (EFV)
RxNorm normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Efavirenz (EFV) (600 mg QD) + TDF/FTC (300/200 mg QD)
Trial: 22963595
Drug: Computerized Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computerized Cognitive Behavioral Therapy (cCBT)
Trial: 12608543
Drug: Oxybutynin transdermal
RxNorm normalized name: oxyBUTYnin Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxybutynin transdermal system (TDS) applied to abdomen
Trial: 12608543
Drug: Oxybutynin transdermal
RxNorm normalized name: oxyBUTYnin Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxybutynin transdermal system (TDS) applied to buttock and hip
Trial: 12608543
Drug: Oxybutynin transdermal
RxNorm normalized name: oxyBUTYnin Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxybutynin transdermal system (TDS)
Trial: 12608543
Drug: In vitro
RxNorm normalized name: glucuronidase in vitro test
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In vitro Oxybutynin skin absorption
Trial: 8619355
Drug: Iobitridol (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iobitridol (300 mg I/ml)
Trial: 6206687
Drug: Iohexol (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iohexol (300 mg I/ml)
Trial: 1768163
Drug: Pamidronate 30
RxNorm normalized name: pamidronate 30 mg intravenous powder for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pamidronate 30 mg weekly for six weeks (Group 1)
Trial: 1768163
Drug: Pamidronate 60
RxNorm normalized name: pamidronate 60 mg intravenous powder for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pamidronate 60 mg weekly for three weeks (Group 1A)
Trial: 1768163
Drug: Pamidronate 45
RxNorm normalized name: Pamidronate
DrugBank: Pamidronic acid (DB00282)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pamidronate 45 mg every three months for one year (Group 2)
Trial: 6755247
Drug: Hepatitis B
RxNorm normalized name: HEPATITIS B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatitis B vaccine (Heptavax‐B)
Trial: 23567441
Drug: venlafaxine XR
RxNorm normalized name: venlafaxine Extended Release Oral Capsule
DrugBank: Venlafaxine (DB00285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: venlafaxine XR (up to 300 mg/day) for 12 weeks
Trial: 19299803
Drug: Placebo perineural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo perineural femoral infusion
Trial: 17519647
Drug: Placebo (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (250 mg)
Trial: 15292480
Drug: C&E (caffeine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C&E (caffeine 70 mg/dose and ephedra 24 mg/dose)
Trial: 7901473
Drug: Corticosteroids (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroids (40 mg prednisolone daily, tapered and stopped after 12 weeks)
Trial: 3629220
Drug: Intramuscular gold
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular gold therapy
Trial: 3629220
Drug: Oral penicillamine
RxNorm normalized name: Penicillamine
DrugBank: Penicillamine (DB00859)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral penicillamine therapy
Trial: 27487463
Drug: Combined administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined administration of ofloxacin both one day and one hour before IVI (eight doses)
Trial: 12594647
Drug: Discontinuation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation of secondary prophylaxis for PCP
Trial: 9846777
Drug: Gabapentin (titrated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin (titrated from 900 to 3600 mg/d or maximum tolerated dosage)
Trial: 2571354
Drug: Prescription information
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescription information leaflets (PILs) for penicillins, diuretics, and benzodiazepines
Trial: 25532865
Drug: delta-9-THC (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: delta-9-THC (10 mg)
Trial: 18590259
Drug: DP-a (hydrofluoric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DP-a (hydrofluoric acid treatment)
Trial: 18590259
Drug: DP-s (sandblasting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DP-s (sandblasting treatment)
Trial: 18590259
Drug: IC-s (sandblasting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IC-s (sandblasting treatment)
Trial: 18590259
Drug: IC-a (hydrofluoric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IC-a (hydrofluoric acid treatment)
Trial: 15294013
Drug: FP/salmeterol 100/50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FP/salmeterol 100/50 microg twice daily via Diskus inhaler
Trial: 15294013
Drug: FP +
RxNorm normalized name: Coagulation Factor IX (Recombinant), Albumin Fusion Protein (rIX-FP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FP + montelukast 100 microg twice daily via Diskus inhaler plus oral montelukast 10mg once daily
Trial: 7523181
Drug: rhG‐CSF administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhG‐CSF administration
Trial: 7523181
Drug: H 7
RxNorm normalized name: Isolyte S PH 7.4
DrugBank: Sodium phosphate, dibasic, unspecified form (DB14504)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H 7 (10 mumol/l) or H 8 (20 mumol/l) co-incubation
Trial: 1111913
Drug: BCNU 150
RxNorm normalized name: Carmustine
DrugBank: Carmustine (DB00262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: BCNU 150 mg/m2 and vincristine 2 mg/m2 given every 30 days
Trial: 1111913
Drug: DTIC 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTIC 300 mg/m2/day x 6 given every 30 days
Trial: 1111913
Drug: DTIC 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTIC 100 mg/m2/8 hours x 18 given every 30 days
Trial: 28464042
Drug: Etoricoxib 90
RxNorm normalized name: etoricoxib 90 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etoricoxib 90 mg qd for six months (long-term)
Trial: 28464042
Drug: Etoricoxib 90
RxNorm normalized name: etoricoxib 90 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etoricoxib 90 mg qd for six months (short-course)
Trial: 28464042
Drug: Etoricoxib 90
RxNorm normalized name: etoricoxib 90 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etoricoxib 90 mg qd for six months
Trial: 26639505
Drug: D-Worm (herbal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-Worm (herbal medicine)
Trial: 26639505
Drug: Mebandazole (allopathic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mebandazole (allopathic drug)
Trial: 14530608
Drug: Low-dose ACTH
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose ACTH test (LDAT) 0.5 microg/m2
Trial: 14530608
Drug: Standard-dose ACTH
RxNorm normalized name: ACTH
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard-dose ACTH test (SDAT) 250 microg/m2